• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    2/18/22 8:16:16 AM ET
    $BBI
    $BDTX
    $BFRA
    $DRMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BBI alert in real time by email

     

    Gainers

    • Biofrontera (NASDAQ:BFRA) stock moved upwards by 11.8% to $3.49 during Friday's pre-market session. The market value of their outstanding shares is at $98.9 million.
    • Paratek Pharmaceuticals (NASDAQ:PRTK) stock rose 9.76% to $4.27. The market value of their outstanding shares is at $214.3 million.
    • INmune Bio (NASDAQ:INMB) shares increased by 9.38% to $12.0. The market value of their outstanding shares is at $214.1 million.
    • Revelation Biosciences (NASDAQ:REVB) stock rose 7.17% to $2.39. The company's market cap stands at $34.0 million.
    • Black Diamond Therapeutic (NASDAQ:BDTX) stock moved upwards by 6.95% to $4.0. The market value of their outstanding shares is at $144.9 million.
    • NeuroOne Medical Tech (NASDAQ:NMTC) stock increased by 6.74% to $2.85. The market value of their outstanding shares is at $46.1 million. As per the news, the Q1 earnings report came out 4 days ago.

     

    Losers

    • 10x Genomics (NASDAQ:TXG) stock decreased by 23.1% to $73.0 during Friday's pre-market session. The company's market cap stands at $8.1 billion. As per the press release, Q4 earnings came out 2 days ago.
    • Marker Therapeutics (NASDAQ:MRKR) stock fell 19.18% to $0.5. The company's market cap stands at $41.4 million. As per the press release, Q4 earnings came out 2 days ago.
    • Larimar Therapeutics (NASDAQ:LRMR) shares fell 7.11% to $3.66. The market value of their outstanding shares is at $64.8 million.
    • Brickell Biotech (NASDAQ:BBI) shares decreased by 6.53% to $0.24. The company's market cap stands at $27.1 million.
    • Dermata Therapeutics (NASDAQ:DRMA) shares decreased by 6.35% to $1.18. The market value of their outstanding shares is at $9.8 million.
    • Orphazyme (NASDAQ:ORPH) stock declined by 5.01% to $2.09. The market value of their outstanding shares is at $73.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BBI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBI
    $BDTX
    $BFRA
    $DRMA

    CompanyDatePrice TargetRatingAnalyst
    10x Genomics Inc.
    $TXG
    12/11/2025Buy → Neutral
    Citigroup
    Black Diamond Therapeutics Inc.
    $BDTX
    12/3/2025Buy → Neutral
    Guggenheim
    10x Genomics Inc.
    $TXG
    12/2/2025$20.00Overweight → Equal-Weight
    Morgan Stanley
    Black Diamond Therapeutics Inc.
    $BDTX
    11/18/2025$9.00Overweight
    Piper Sandler
    Black Diamond Therapeutics Inc.
    $BDTX
    10/16/2025$8.00Buy
    Stifel
    10x Genomics Inc.
    $TXG
    9/11/2025$15.00Neutral
    Piper Sandler
    Black Diamond Therapeutics Inc.
    $BDTX
    9/4/2025$8.00Buy
    Guggenheim
    Black Diamond Therapeutics Inc.
    $BDTX
    7/1/2025$11.00Outperform
    Raymond James
    More analyst ratings

    $BBI
    $BDTX
    $BFRA
    $DRMA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Dermata Therapeutics Inc.

    SCHEDULE 13D/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    2/23/26 7:56:24 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    INmune Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Inmune Bio, Inc. (0001711754) (Filer)

    2/23/26 4:05:29 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    INmune Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Inmune Bio, Inc. (0001711754) (Filer)

    2/19/26 4:00:25 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BBI
    $BDTX
    $BFRA
    $DRMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's Webinar

    Boca Raton, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) ("INmune" or the "Company"), a late-stage biotechnology company focused on inflammation and immunology, will host a webinar focused on the registrational pathway of XPro1595 ("XPro™") for the treatment of early Alzheimer's disease on February 27, 2026 at 9:30 a.m. ET. Post the completion of the Phase 2 MINDFuL trial, along with feedback from the FDA in a recent End-Of-Phase 2 meeting, the Company has received alignment supporting advancement to a registrational study in patients with Alzheimer's Disease with biomarkers of Inflammation. Webinar Focus: From Phase 2 Results to Phase 3 Readiness XPro™ is a next

    2/23/26 9:25:00 AM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    10x Genomics to Participate in the 46th Annual TD Cowen Health Care Conference

    PLEASANTON, Calif., Feb. 19, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, at 11:50 a.m. Eastern Time. Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 30 days after the event.About 10x Genomics10

    2/19/26 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB

    Clinical investigators from the trial to share real-world experience treating RDEB patients with CORDStrom and present new data from the MissionEB clinical study Boca Raton, FL, Feb. 19, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:INMB) ("INmune" or the "Company"), a late-stage biotechnology company focused on inflammation and immunology, will host a webinar on CORDStrom for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) on February 26, 2026 at 1:00 p.m. ET.  The session will focus on the latest results from the MissionEB Phase III clinical trial, specifically highlighting the systemic disease-modifying capabilities of CORDStrom™ in patients with RDEB Webinar F

    2/19/26 12:15:00 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BBI
    $BDTX
    $BFRA
    $DRMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    10x Genomics downgraded by Citigroup

    Citigroup downgraded 10x Genomics from Buy to Neutral

    12/11/25 8:24:15 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Black Diamond Therapeutics downgraded by Guggenheim

    Guggenheim downgraded Black Diamond Therapeutics from Buy to Neutral

    12/3/25 12:43:23 PM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    10x Genomics downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded 10x Genomics from Overweight to Equal-Weight and set a new price target of $20.00

    12/2/25 8:22:39 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BBI
    $BDTX
    $BFRA
    $DRMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    * Director by Deputization Flynn James E bought $30,000,000 worth of shares (9,375,000 units at $3.20) (SEC Form 4)

    4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

    8/4/25 6:28:33 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Mcclurg Ronald W. bought $100,000 worth of shares (200,000 units at $0.50), increasing direct ownership by 82% to 444,117 units (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    4/7/25 4:47:21 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    CEO and President Rosa David A bought $50,000 worth of shares (100,000 units at $0.50), increasing direct ownership by 9% to 1,161,289 units (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    4/7/25 4:38:47 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $BBI
    $BDTX
    $BFRA
    $DRMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Mertens Steve covered exercise/tax liability with 7,376 shares, decreasing direct ownership by 5% to 153,047 units (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    2/20/26 2:27:42 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Business Development Director Christianson Mark covered exercise/tax liability with 1,812 shares, decreasing direct ownership by 0.79% to 228,920 units (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    2/20/26 2:20:36 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    CEO and President Rosa David A covered exercise/tax liability with 71,325 shares, decreasing direct ownership by 6% to 1,082,590 units (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    2/20/26 2:15:19 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $BBI
    $BDTX
    $BFRA
    $DRMA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NUZYRA issued to PARATEK PHARMS INC

    Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-10) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 05/27/2021. Application Category: NDA, Application Number: 209817, Application Classification: Efficacy

    5/31/21 5:18:25 AM ET
    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NUZYRA issued to PARATEK PHARMS INC

    Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-11) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 05/27/2021. Application Category: NDA, Application Number: 209816, Application Classification: Efficacy

    5/31/21 5:18:25 AM ET
    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NUZYRA

    Submission status for PARATEK PHARMS INC's drug NUZYRA (SUPPL-11) with active ingredient OMADACYCLINE TOSYLATE has changed to 'Approval' on 01/11/2021. Application Category: NDA, Application Number: 209817, Application Classification: Labeling

    1/26/21 5:26:59 AM ET
    $PRTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBI
    $BDTX
    $BFRA
    $DRMA
    Leadership Updates

    Live Leadership Updates

    View All

    Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

    HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company's Board of Directors, effective November 1, 2025. Ms. Penkus Corzo has vast experience as a biopharma executive, drug developer and independent board director with more than 30 years of global leadership spanning R&D, clinical trials, regulatory approvals, commercialization, and corporate strategy across multiple therapeutic modalities and in

    11/5/25 7:30:00 AM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary

    EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has strengthened its management team with the appointment of Emily Johns as General Counsel and Corporate Secretary. Dave Rosa, President and CEO of NeuroOne said, "We are excited to welcome Emily to NeuroOne especially after working with her for almost a decade. Her legal acumen and experience navigating dynamic, fast-growing organizations will be invaluable as we continue to scale our business.

    6/3/25 8:30:00 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

    Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced the retirement of George F. Tidmarsh, MD, PhD from the Company's Board of Directors. "The team at Revelation wholeheartedly thanks Dr. Tidmarsh for his guidance and support over the past 5 years," said James Rolke, Chief Executive Officer of Revelation. "While he will be missed, we wish him the best of luck in his newest endeavor." "The Revelation team is dedicated to developing innovative therapies to improve the clinical outcomes for patients in need," said Dr. Tidmarsh. "I thank them for their passio

    5/23/25 4:05:00 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBI
    $BDTX
    $BFRA
    $DRMA
    Financials

    Live finance-specific insights

    View All

    10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026

    PLEASANTON, Calif., Feb. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided its outlook for 2026. Recent Updates Revenue was $166.0 million for the fourth quarter of 2025, representing a 1% increase over the corresponding period of 2024. Revenue was $642.8 million for the full year of 2025. Excluding $44.1 million of non-recurring revenue related to patent litigation settlements, full-year revenue was $598.7 million, rep

    2/12/26 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

    PLEASANTON, Calif., Jan. 22, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Thursday, February 12, 2026. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

    1/22/26 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

    Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no new safety signals observed to datePFS data for 1L NSCLC patients expected in Q2 2026; Company continues to explore partnership opportunities for pivotal development of silevertinibBased on encouraging CNS activity of silevertinib in multiple trials across NSCLC and GBM, Company plans to initiate a randomized Phase 2 trial of silevertinib in newly diagnosed GBM patients in 1H 2026; initial data anticipated in 2028Cash, cash equivalents, and investments of $135.5 million as of September 30, 2025;

    12/3/25 7:01:00 AM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BBI
    $BDTX
    $BFRA
    $DRMA
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Breaking: Stock Acquired at INmune Bio Inc. on Jun 26

    Recently, on June 26, 2024, Director Juda Scott bought $36,350 worth of shares (5,000 units at $7.27) (SEC Form 4) in INmune Bio Inc. This insider purchase is significant as it indicates confidence from someone within the company towards its future growth prospects. It's interesting to note that this purchase by Juda Scott follows a series of transactions by other insiders in the company. For example, Moss David J bought $149,993 worth of shares (18,028 units at $8.32) on April 24, 2024, increasing direct ownership by 1% to 1,268,179 units. This demonstrates a consistent trend of insider buying within the organization. Looking back at previous transactions, on May 16, 2024, several key ins

    6/26/24 2:54:12 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BBI
    $BDTX
    $BFRA
    $DRMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NeuroOne Medical Technologies Corporation

    SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

    11/26/24 8:42:10 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dermata Therapeutics Inc.

    SC 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    11/14/24 5:07:13 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Larimar Therapeutics Inc.

    SC 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)

    11/14/24 5:05:19 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care